Treatment: Present status and new trends

Inborn Metabolic Diseases: Diagnosis and Treatment

Volumn , Issue , 2006, Pages 81-97

  Walter, John H ^a   Wraith, J Ed ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745093174     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-28785-8_5     Document Type: Chapter

References (72)

1. Acosta PB, Stepnick Gropper S, Clarke Sheehan N et al (1987) Trace element status of PKU children ingesting an elemental diet. J Parenter Enteral Nutr 11:287-292
2. Safos S, Chang TM (1995) Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. Artif Cells Blood Substit Immobil Biotechnol 23:681-692
3. Brown-Harrison MC, Nada MA, Sprecher H et al (1996) Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 58:59-65
4. Pollitt RJ (1995) Disorders of mitochondrial long-chain fatty acid oxidation. J Inherit Metab Dis 18:473-490
5. Morris AA, Clayton PT, Surtees RA et al (1997) Clinical outcomes in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 131:938
6. Irons M, Elias ER, Abuelo D et al (1997) Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet 68:311-314
7. Moser HW, Fatemi A, Zackowski K et al (2004) Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 29:1003-1016
8. Moser HW, Raymond GV, Lu SE et al (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 62:1073-1080
9. Cox TM, Aerts JM, Andria G et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513-526
10. Jaeken J, Detheux M, Van Maldergem L et al (1996) 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 74:542-545
11. Stockler S, Hanefeld F, Frahm J (1996) Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 348:789-790
12. Kreuder J, Otten A, Fuder H et al (1993) Clinical and biochemical consequences of copper-histidine therapy in Menkes disease. Eur J Pediatr 152:828-832
13. Kaler SG, Buist NR, Holmes CS et al (1995) Early copper therapy in classic Menkes disease patients with a novel splicing mutation [7 comments]. Ann Neurol 38:921-928
14. Niehues R, Hasilik M, Alton G et al (1998) Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy [see comments]. J Clin Invest 101:1414-1420
15. Klepper J, Diefenbach S, Kohlschutter A et al (2004) Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins Leukot Essent Fatty Acids 70:321-327
16. Ramaekers VT, Rothenberg SP, Sequeira JM et al (2005) Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 352:1985-1991
17. Davies SE, Iles RA, Stacey TE et al (1991) Carnitine therapy and metabolism in the disorders of propionyl-CoA metabolism studied using 1H-NMR spectroscopy. Clin Chim Acta 204:263-277
18. De Sousa C, Chalmers RA, Stacey TE et al (1986) The response to L-carnitine and glycine therapy in isovaleric acidaemia. Eur J Pediatr 144:451-456
19. Rutledge SL, Berry GT, Stanley CA et al (1995) Glycine and L-carnitine therapy in 3-methylcrotonyl-CoA carboxylase deficiency. J Inherit Metab Dis 18:299-305
20. Walter JH (1996) L-Carnitine. Arch Dis Child 74:475-478
21. Lee PJ, Harrison EL, Jones MG et al (2005) L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: a pilot study. J Inherit Metab Dis 28:141-152
22. Waber LJ, Valle D, Neill C et al (1982) Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 101:700-705
23. Igisu H, Matsuoka M, Iryo Y (1995) Protection of the brain by carnitine. Sangyo Eiseigaku Zasshi 37:75-82
24. Hamosh A, McDonald JW, Valle D et al (1992) Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant [see comments]. J Pediatr 121:131-135
25. Alemzadeh R, Gammeltoft K, Matteson K (1996) Efficacy of lowdose dextromethorphan in the treatment of nonketotic hyperglycinemia. Pediatrics 97(6 Pt 1):924-926
26. Matsuo S, Inoue F, Takeuchi Y et al (1995) Efficacy of tryptophan for the treatment of nonketotic hyperglycinemia: a new therapeutic approach for modulating the N-methyl-D-aspartate receptor. Pediatrics 95:142-146
27. Ulloa-Aguirre A, Janovick JA, Brothers SP et al (2004) Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821-837
28. Mills PB, Surtees RA, Champion MP et al (2005) Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox (am) ine 5'-phosphate oxidase. Hum Mol Genet 14:1077-1086
29. Desnick RJ (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27:385-410
30. Frustaci A, Chimenti C, Ricci R et al (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactoseinfusion therapy. N Engl J Med 345:25-32
31. Barshop BA, Naviaux RK, McGowan KA et al (2004) Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab 83:138-149
32. Hobbs JR, Hugh-Jones K, Barrett AJ et al (1981) Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2:709-712
33. Weisstein JS, Delgado E, Steinbach LS et al (2004) Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24:97-101
34. Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350:1960-1969
35. Escolar ML, Poe MD, Provenzale JM et al (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 352:2069-2081
36. Sauer M, Grewal S, Peters C (2004) Hematopoietic stem cell transplantation for mucopolysaccharidoses and leukodystrophies. Klin Padiatr 216:163-168
37. Kayler LK, Merion RM, Lee S et al (2002) Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 6:295-300
38. Chakrapani A, Sivakumar P, McKiernan PJ et al (2002) Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J Pediatr 140:261-263
39. Leonard JV, Walter JH, McKiernan PJ (2001) The management of organic acidaemias: the role of transplantation. J Inherit Metab Dis 24:309-311
40. Muraca M, Gerunda G, Neri D et al (2002) Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 359:317-318
41. Horslen SP, McCowan TC, Goertzen TC et al (2003) Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 111(6 Pt 1):1262-1267
42. Van't Hoff WG, Dixon M, Taylor J et al (1998) Combined liver-kidney transplantation in methylmalonic acidemia. J Pediatr 132:1043-1044
43. Jamieson NV, Watts RW, Evans DB et al (1991) Liver and kidney transplantation in the treatment of primary hyperoxaluria. Transplant Proc 23:1557-1558
44. Gruessner RW (1998) Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I [letter]. N Engl J Med 338:1924
45. Hershfield MS, Buckley RH, Greenberg ML et al (1987) Treatment of adenosine deaminase deficiency with polyethylene glycolmodified adenosine deaminase. N Engl J Med 316:589-596
46. Schiffmann R, Brady RO (2002) New prospects for the treatment of lysosomal storage diseases. Drugs 62:733-742
47. Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113:112-119
48. Charrow J, Esplin JA, Gribble TJ et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158:1754-1760
49. Baldellou A, Andria G, Campbell PE et al (2004) Paediatric nonneuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 163:67-75
50. Grabowski GA, Andria G, Baldellou A et al (2004) Pediatric nonneuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 163:58-66
51. Vellodi A, Bembi B, de Villemeur TB et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24:319-327
52. Schiffmann R, Kopp JB, Austin HA, III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743-2749
53. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 345:9-16
54. Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubleblinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581-588
55. Harmatz P, Whitley CB, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574-580
56. Van den Hout JM, Kamphoven JH, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448-e457
57. Winkel LP, Van den Hout JM, Kamphoven JH et al (2004) Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55:495-502
58. Muenzer J, Calikoglu M, Towle D, McCandless S, Kimura A (2003) The one year experience of enzyme replacement therapy for mucopolysaccharidosis type II (Hunter syndrome). Am J Hum Genet 73:623
59. Mango RL, Xu L, Sands MS et al (2004) Neonatal retroviral vectormediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 82:4-19
60. Aiuti A, Ficara F, Cattaneo F et al (2003) Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol 3:461-466
61. Charache S (1993) Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies. Experientia 49:126-132
62. Dover GJ, Humphries RK, Moore JG et al (1986) Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 67:735-738
63. Charache S, Dover G, Smith K et al (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta- globin gene complex. Proc Natl Acad Sci U S A 80:4842-4846
64. Rubenstein RC, Egan ME, Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100:2457-2465
65. Kemp S, Wei HM, Lu JF et al (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 4:1261-1268
66. McGuinness MC, Zhang HP, Smith KD (2001) Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol Genet Metab 74:256-263
67. Zeng WQ, Al Yamani E, Acierno JS, Jr et al (2005) Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 77:16-26
68. Koga Y, Akita Y, Nishioka J et al (2005) L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64:710-712
69. Kjaergaard S, Kristiansson B, Stibler H et al (1998) Failure of shortterm mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr 87:884-888
70. Mayatepek E, Schroder M, Kohlmuller D et al (1997) Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr 86:1138-1140
71. Ostman-Smith I, Brown G, Johnson A et al (1994) Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid. Br Heart J 72:349-353
72. Quinzii C, Naini A, Salviatil et al (2006) A mutation in para-hydroxy benzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am I Humbenet 78:345-349